Vuja De is dedicated to developing cancer metastasis treatments that prevent cancer progression and recurrence. Our strategy is to develop products first for osteosarcoma, a rare bone cancer that largely effects adolescents, and then extend to other cancers. We utilize leading laboratory technologies for metastatic preclinical endpoints in combination with Comparative Oncology to de-risk and inform product development and maximize likelihood for successful human oncology clinical trials. We are testing repurposed drugs that have previously been in human clinical trials, as well as novel preclinical drugs.
In Comparative Oncology, canine patients with naturally occurring cancer are included in clinical trials for benefit of humans and human's best friend. Dog osteosarcoma is highly relevant to human osteosarcoma; drugs effective in the dog are highly relevant to the human. A further advantage of dogs that is crucial in cancer recurrence trials is the that fact that in dogs the cancer process is sped up, so that what happens over a time frame of a few years in humans is compressed into months in dogs.
Company Details
- Employees
- 6
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://vujade-life.com/
Vuja De Sciences Questions
Vuja De Sciences's website is https://vujade-life.com/
Vuja De Sciences's LinkedIn profile is https://www.linkedin.com/company/vuja-de-sciences
Vuja De Sciences has
6 employees.
View email and phone details for 6
employees at Vuja De Sciences.
Vuja De Sciences's industry is
Biotechnology Research
Vuja De Sciences's top competitors are
Nona Biosciences,
Sbh Sciences,
Beam Therapeutics,
Jounce Therapeutics, Inc.,
Navitor Pharmaceuticals,
Sola Biosciences,
Theranica,
Congruence Therapeutics,
Emtora Biosciences,
Neurodex.
Vuja De Sciences's categories are Biotechnology Research
Vuja De Sciences's founding year is 2017
